Insulin Glargine

Introduction Overview

Generic Name

insulin glargine

Brand Name

Semglee

Dosage Form

Subcutaneous injection (long-acting insulin)

Drug Class

Insulin

Pharmacokinetics

Absorption:
Insulin glargine, the active ingredient in Semglee, is a long-acting insulin analog designed to provide a consistent and prolonged release of insulin after subcutaneous injection. Upon injection, insulin glargine forms microprecipitates in the subcutaneous tissue at physiological pH that slowly release small amounts of insulin glargine monomers. This leads to a relatively constant concentration/time profile without pronounced peaks over an extended duration up to 24 hours. Absorption is slow and steady, providing basal insulin levels to control blood glucose between meals and overnight. The onset of action typically occurs several hours post-injection, distinguished from rapid-acting insulins. Factors such as injection site, blood flow, and temperature can influence absorption rates.

Distribution:
Insulin glargine is distributed primarily within the extracellular fluid compartment after absorption into the bloodstream. It binds minimally to plasma proteins other than insulin receptors and circulates predominantly as free active monomers. The volume of distribution for insulin glargine approximates that of total body extracellular water. Due to its pharmacologic role, insulin glargine targets insulin receptors on muscle, fat, and hepatic tissue to mediate glucose uptake and utilization.

Metabolism:
Insulin glargine undergoes enzymatic cleavage upon absorption, converting into active metabolites M1 and M2 which exhibit similar pharmacodynamic effects to native insulin. These metabolites contribute substantially to the drug's sustained activity profile. Insulin glargine and its metabolites are predominantly catabolized in the liver, kidneys, and peripheral tissues into inactive metabolites, largely through insulin-degrading enzyme pathways. The metabolic clearance rate is a function of receptor-mediated internalization and proteolysis.

Elimination:
The elimination of insulin glargine and its metabolites occurs mainly via renal and hepatic degradation pathways. Insulin glargine itself is not excreted unchanged in urine or feces. The metabolic degradation products lack pharmacological activity and are eventually cleared. The half-life of insulin glargine is approximately 12 hours, but its pharmacodynamic effect extends up to 24 hours due to sustained absorption from the subcutaneous depot. Impaired renal or hepatic function may alter insulin clearance, necessitating dose adjustments in some patients.

Dosage Forms

Available Dosage Forms:
Semglee is available as subcutaneous injection formulations. The available presentation is a Multi-Dose Vial containing 100 units/mL insulin glargine at a concentration of 1,000 units/10 mL (100 units/mL). The previously available Semglee Autoinjector pen with 300 units/3 mL (100 units/mL) concentration has been discontinued and voluntarily revoked.

Dosages for Adults and Adolescents:
The dosage regimen with Semglee is individualized according to the patient's metabolic needs, blood glucose monitoring results, and glycemic control goals. Typically, Semglee is administered once daily subcutaneously at the same time each day. For type 1 diabetes, Semglee is used in combination with short-acting insulin before meals. For type 2 diabetes, it may be used as monotherapy or with other antidiabetic agents. Initial dosing recommendations often begin with 10 units per day or 0.2 units/kg/day, with titration based on fasting glucose levels and clinical response.

Specific Patient Populations:
In pediatric patients aged 6 years and above with type 1 diabetes, Semglee can be used safely with adjusted dosing regimens and careful monitoring. Use in children younger than 6 years, and in pediatric type 2 diabetes patients is not established due to lack of sufficient data. In patients with renal or hepatic impairment, dose adjustments may be necessary. Special caution is advised during pregnancy and lactation; insulin requirements may change, and close monitoring is essential.

Clinical Guidelines:
Semglee should be injected subcutaneously in the abdomen, thigh, or upper arm, rotating injection sites to reduce the risk of lipodystrophy. It must not be administered intravenously or via insulin pumps, nor mixed with other insulins. Dose adjustments should avoid abrupt changes in concentration or brand to prevent hypoglycemia or hyperglycemia.

Mechanism Of Action

Semglee (insulin glargine) is a recombinant human insulin analog formulated to provide prolonged basal insulin levels with a duration of action up to 24 hours. Its molecular structure features substitution of asparagine with glycine at position 21 of the A-chain and addition of two arginine molecules at the C-terminal of the B-chain. These modifications shift the isoelectric point toward neutrality, causing the insulin to be less soluble at physiological pH and resulting in the formation of microprecipitates upon subcutaneous injection.

These microprecipitates act as a depot that slowly and steadily releases insulin glargine monomers into systemic circulation, providing a near-constant concentration of active insulin without pronounced peaks seen with other insulins. Once in circulation, insulin glargine binds to insulin receptors on target cells including adipose tissue, skeletal muscle, and liver, stimulating cellular glucose uptake, glycogen synthesis, and inhibition of hepatic gluconeogenesis, collectively lowering blood glucose levels.

At the cellular level, insulin glargine activates the insulin receptor tyrosine kinase, initiating phosphorylation cascades involving insulin receptor substrates and downstream signaling pathways such as PI3K/Akt and MAPK. These pathways mediate translocation of glucose transporter type 4 (GLUT4) to the plasma membrane, facilitating glucose uptake into cells. Additionally, insulin glargine inhibits lipolysis and proteolysis and enhances lipid and protein synthesis.

Clinical studies have demonstrated insulin glargine's consistent and predictable pharmacodynamic profile, resulting in improved fasting blood glucose control and reduced risk of nocturnal hypoglycemia compared to intermediate-acting insulins. Compared to other long-acting insulin analogs like insulin detemir and insulin degludec, insulin glargine provides effective basal glycemic control with distinct pharmacokinetics. Its biosimilar nature as Semglee ensures similar clinical efficacy and safety to the reference insulin glargine products, supported by comprehensive regulatory evaluations.

Pharmacological Actions

Acts as a long-acting basal insulin replacement providing sustained glucose-lowering effect for up to 24 hours.
Mimics endogenous insulin by binding to insulin receptors to stimulate cellular uptake of glucose.
Inhibits hepatic glucose production through suppression of gluconeogenesis.
Promotes glycogen synthesis in liver and muscle tissues.
Enhances lipogenesis and inhibits lipolysis in adipose tissue.
Facilitates protein synthesis and reduces proteolysis.
Regulates blood glucose homeostasis, helping to maintain euglycemia in diabetic patients.
Exhibits a steady, peakless pharmacodynamic profile reducing fluctuations in plasma insulin levels.
Reduces risk of hypoglycemia compared to intermediate-acting insulins when dosed appropriately.
Provides basal insulin coverage to complement mealtime rapid-acting insulin therapy in type 1 diabetes.
Therapeutic equivalence with reference insulin glargine products and biosimilars.
Minimal immunogenicity profile owing to recombinant human insulin structure.
Does not cross-react significantly with insulin-like growth factor-1 receptors, minimizing mitogenic risk.

Therapeutic Or Clinical Uses

Improving glycemic control in adults with type 1 diabetes mellitus as basal insulin therapy.
Managing blood glucose in adults with type 2 diabetes mellitus requiring insulin supplementation.
Treatment of type 1 diabetes in pediatric patients aged 6 years and older in combination with rapid-acting insulins.
Providing steady basal insulin coverage to reduce fasting and between-meal hyperglycemia.
Adjunct to diet and exercise in type 2 diabetes management when oral agents or non-insulin injectables are insufficient.
Utilized in insulin replacement therapy for insulin-deficient states.
Alternative to intermediate-acting insulins to lower risk of nocturnal hypoglycemia.
Controlling blood glucose to prevent microvascular and macrovascular complications of diabetes.
Used in basal-bolus insulin regimens for flexible intensive insulin therapy.
Biosimilar option to established insulin glargine products providing cost-effective therapy.
May be used in patients intolerant to other basal insulins or with variable absorption profiles.
Part of individualized treatment plans tailored by healthcare providers based on patient needs.
Important component in diabetes management during pregnancy under specialist guidance.
Employed in clinical practice for insulin titration based on blood glucose monitoring.

Side Or Adverse Effects

Hypoglycemia, characterized by symptoms such as dizziness, sweating, hunger, irritability, and tremors.
Injection site reactions including redness, swelling, itching, and pain at the injection site.
Lipodystrophy, including lipohypertrophy and lipoatrophy, due to repeated injections at the same site.
Allergic reactions ranging from localized skin rash to systemic anaphylaxis.
Weight gain secondary to improved glycemic control and insulin-mediated anabolic effects.
Peripheral edema and fluid retention.
Potential for hypokalemia presenting with muscle cramps, constipation, irregular heartbeat, and weakness.
Rare occurrences of injection site infection if aseptic technique is not followed.
Possible development of insulin antibodies with prolonged treatment.
Swelling or rapid weight gain indicating fluid retention.
Symptoms of severe hypoglycemia including confusion, blurred vision, seizures, or loss of consciousness.
Rare hypersensitivity reactions such as angioedema or generalized rash.
Risk of hypoglycemia may be increased when combined with other glucose-lowering agents.
Skin thickening or dimpling at injection sites after prolonged use.
Gastrointestinal symptoms related to hypoglycemia like nausea during episodes.

Precautions

Careful dose titration to minimize risk of hypoglycemia.
Rotate injection sites to reduce risk of lipodystrophy and local skin reactions.
Monitor blood glucose levels regularly to guide dose adjustments.
Use cautiously in patients with renal or hepatic impairment, as clearance may be affected.
Avoid using Semglee during episodes of hypoglycemia or diabetic ketoacidosis.
Not recommended for use in children under 6 years of age due to lack of established safety and efficacy.
Inform healthcare providers of all concurrent medications, especially oral antidiabetics like pioglitazone or rosiglitazone.
Pregnant or breastfeeding patients should use Semglee under medical supervision with appropriate glycemic monitoring.
Avoid sharing injection pens or syringes to prevent transmission of infections.
Use only the prescribed product and avoid switching brands or formulations without medical advice.
Educate patients on recognizing and managing symptoms of hypo- and hyperglycemia.
Avoid injecting into areas of damaged skin, scars, or inflammation.
Maintain proper storage conditions to preserve insulin potency.
Adjust doses during periods of stress, illness, or changes in diet and physical activity.
Caution when driving or operating machinery until individual response to therapy is established.

Warnings

Do not use Semglee if experiencing hypoglycemia or allergic reaction to insulin glargine or any ingredient in the formulation.
Risk of severe hypoglycemia if dosing errors occur or insulin is administered excessively.
Never share injection pens or syringes to prevent serious infections.
Hypoglycemia may be life-threatening if not recognized and treated promptly.
Use caution in patients with heart failure or other cardiac conditions, especially when combined with certain antidiabetic agents.
Semglee is not intended for treatment of diabetic ketoacidosis.
Avoid injecting intravenously or intramuscularly; intended only for subcutaneous administration.
Dose requirements may change during illness, stress, or changes in exercise and diet.
Monitoring for signs of allergic reactions including rash, swelling, and breathing difficulties is essential.
Improper storage (freezing or exposure to heat) may reduce effectiveness and increase risk of adverse events.
Not established as safe or effective in children under 6 years of age or in pediatric type 2 diabetes.
Patients should carry identification indicating insulin use for emergency situations.
Abrupt changes in insulin type or dose can precipitate hypo- or hyperglycemia.
Use with caution when combining with drugs that affect glucose metabolism or mask hypoglycemia.
Mandatory medical supervision is required for dose changes and management during pregnancy.

Contraindication

Known hypersensitivity or allergy to insulin glargine or any constituents of Semglee.
During episodes of hypoglycemia (low blood sugar).
In patients with diabetic ketoacidosis, requiring rapid-acting insulin administration and fluid replacement.
Not approved for treatment of type 2 diabetes in pediatric patients of any age.
Use not established in children less than 6 years old with type 1 diabetes.
Contraindicated in individuals where insulin therapy is not clinically indicated.
Do not use Semglee in patients with acute critical illness requiring intensive volume replacement or steroid therapy without close monitoring.
Avoid in cases of acute conditions that may affect insulin sensitivity without adjustment.
Contraindicated in patients with prior severe adverse reactions to insulin glargine products.
Not to be used intravenously or intramuscularly.
Do not use if insulin has been exposed to freezing or temperature abuse compromising drug integrity.
Contraindicated in patients unwilling or unable to self-monitor blood glucose and manage insulin therapy.
Avoid use when infection at the proposed injection site is present.
Contraindicated in concurrent treatment with agents causing severe unpredictable alterations in blood glucose without strict monitoring.
Do not substitute for other biologic insulins without healthcare provider evaluation.

Drug Interactions

Oral antidiabetic agents such as pioglitazone and rosiglitazone may increase risk of heart failure when used with insulin.
Other glucose-lowering drugs may potentiate hypoglycemic effects, necessitating dose adjustment of semglee.
Sympatholytic agents (beta-blockers, clonidine) may mask symptoms of hypoglycemia, delaying recognition.
Diuretics, corticosteroids, thyroid hormones, and sympathomimetics can reduce insulin effectiveness and increase blood sugar.
Alcohol may unpredictably potentiate or antagonize insulin effects on glucose metabolism, affecting glycemic control.
Certain drugs like salicylates and sulfonamides may enhance hypoglycemic actions.
Drugs affecting potassium levels can compound risks of hypokalemia induced by insulin therapy.
Concomitant use of glucocorticoids can induce insulin resistance and higher insulin requirements.
Drugs such as MAO inhibitors can increase insulin sensitivity, requiring monitoring.
Estrogens and oral contraceptives may influence insulin dose requirements.
Beta-adrenergic blockers can inhibit counter-regulatory adrenergic responses to hypoglycemia.
ACE inhibitors may potentiate hypoglycemia in some patients.
Concurrent use with other injectable drugs may increase infection risk if injection sites overlap without proper hygiene.
Some anesthetics and muscle relaxants can alter glycemic control during surgical procedures requiring insulin adjustments.
Drug interactions necessitate close monitoring and possible dose modifications to minimize adverse effects.

Preparations Of The Drug

Semglee multi-dose vial: 100 units/mL (U-100), 1,000 units/10 mL solution for subcutaneous injection.
Previously available Semglee autoinjector pen (300 units/3 mL) has been discontinued and voluntarily revoked.
Formulated as a clear, colorless, aqueous solution of insulin glargine using recombinant DNA technology in E. coli.
Supplied in vials compatible with insulin syringes calibrated for U-100 insulin dosing.
Stable when stored refrigerated between 2°C and 8°C prior to first use.
After opening, vials should be stored below 86°F (30°C) and used within 28 days to ensure potency.
No preservatives added beyond standard formulation components; must be handled aseptically.
Provided with detailed patient instructions for preparation, injection technique, and storage.
Available in pharmacy and hospital settings as an injectable biosimilar insulin glargine product.
Manufactured under stringent regulatory and quality control standards to ensure biosimilarity and efficacy.
Packaging includes patient leaflets advising on rotation of injection sites and hypoglycemia management.
Designed for once-daily subcutaneous administration to maintain steady basal insulin levels.
Not mixed with other insulin formulations due to potential alterations in pharmacokinetics.
Disposable syringes and needles recommended for administration; injection pens must not be shared.
Instructions emphasize avoiding thermal extremes and freezing to preserve drug integrity.